Sanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacks
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it seeks to build investor confidence in its drug pipeline.
'The next battleground': Sanofi exploring opportunities in second generation obesity drugs
Paul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground."
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi's Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 billion, including new COPD approval. Newer drugs like Beyfortus and Altuviiio show strong growth, offsetting challenges from biosimilars and generic competition.
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn's disease.
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
